Research library
The research library
Every primary source behind a claim on this site, tier-graded for provenance and tagged for the strength of the evidence it carries.
- Sources indexed
- 221
- Peptides covered
- 44
- Tier 1 share
- 0%
- Matching filter
- 4
F·Filter
Reset allT3·Expert-primary work
Domain-expert primary sources outside the journal pipeline — lectures, podcasts, position papers.
4 sources
- 2026Cohortmoderate
Semaglutide is associated with improved breast cancer survival, lower metastatic burden, and a dose-survival relationship uncoupled from weight-loss magnitude
Murugadoss K, Venkatakrishnan AJ, Soundararajan V · medRxiv (preprint)
In a federated EHR network of nearly 29 million patients with 1:1 propensity-matched pooled-comparator analyses, semaglutide-treated breast cancer patients had 54 deaths/2,433 (2.2%) versus 395 deaths/2,433 (16.2%) in metformin/SGLT2i/DPP4i comparators over 24 months (log-rank P<0.001); high-dose semaglutide (≥1.7 mg) had ~1.0% event rate vs ~4.5% in low-dose (0.25–1.0 mg, P=0.034), while weight-loss strata did not separate survival (P=0.22) — and any-metastasis incidence was 7.0% vs 15.0% (rate ratio 0.5, P<0.001).
- 2026Cohortsuggestiven=72
The Association Between Serum MOTS-c Levels and Myocardial Ischemia-Reperfusion Injury in Patients with Acute Myocardial Infarction: A Cross-Sectional Study
Peng L, Li Y, Duan X, +3 · Biomedicines
In 72 acute myocardial infarction patients undergoing PCI, postoperative peripheral serum MOTS-c levels were significantly lower in the 34 patients who developed myocardial ischemia-reperfusion injury versus the 38 who did not, with an adjusted odds ratio of 0.986 (95% CI 0.976-0.996) — the first human clinical-cohort biomarker data linking endogenous MOTS-c to acute cardiac injury.
- 2026Cohortsuggestiven=489,785
Semaglutide is associated with stiffness improvement and broad liver benefits with distinct dose- and weight-linked patterns
Soundararajan V, Venkatakrishnan AJ, Murugadoss K, +3 · medRxiv (preprint)
In a de-identified federated EHR network of 489,785 semaglutide-treated adults plus a paired elastography substudy of 326 patients, median liver stiffness fell from 4.85 to 3.9 kPa (−0.38 kPa, p<0.001); 40.8% achieved ≥20% reduction and 80% of those with cirrhosis-range baseline (≥12.5 kPa) hit that threshold — with stiffness improvement appearing in patients with no weight loss as often as in those with ≥10% weight loss, and hepatic GLP1R expression at only 0.0239% suggesting a largely non-direct mechanism.
- 2026Cohortsuggestiven=63,215
Legacy neuropsychiatric benefit after semaglutide is linked to maximum achieved dose and independent of the maximum weight lost
Murugadoss K, Venkatakrishnan A, Soundararajan V · medRxiv (preprint)
From 489,785 semaglutide-treated adults in a federated EHR network, 63,215 patients with baseline neuropsychiatric conditions showed broadly lower 2-year neuropsychiatric event risk versus propensity-matched metformin, SGLT2i and DPP-4i users; higher attained pre-landmark dose was independently associated with lower post-landmark incidence of substance-related, mood, anxiety, CNS-atrophy, neuromuscular, eating/sleep/behavioral and personality/impulse-control disorders — effects that were weight-loss-independent for most outcomes, with confirmed CNS GLP1R expression in hypothalamus, caudate, putamen, NAcc and cerebellum supporting a direct CNS engagement model.